PLX רווח נקי למניה (EPS TTM) Protalix BioTherapeutics, Inc

The current rolling earnings per share level demonstrates how Protalix BioTherapeutics (PLX) minimizes biotech risks through plant-based protein expression for the therapy of rare pathologies. The parameter value is 0.23, which confirms resilience in low-competition niches. Proprietary technology protects the business from standard analogs, ensuring access to the orphan drug market by reducing drug production costs.

Assessing the investment reliability of equity assets begins with an analysis of the real return the business generates per unit of capital. Net income per share over the last four quarters measures the final financial result excluding paper revaluations, reflecting the efficiency of Protalix BioTherapeutics (PLX) and its sustainable transition to plant-based biosynthesis, which allows for an assessment of the company's fundamental stability via this chart.